New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-010 and KEYNOTE-001 in Advanced Non-Small Cell Lung Cancer, Including Survival Data, To Be Presented at 2016 ASCO Annual Meeting

Dateline City:

KENILWORTH, N.J.

New Analysis from KEYNOTE-010, Comparing KEYTRUDA to Chemotherapy, Shows Improved Survival Benefit in Patients with Increased Levels of PD-L1 Expression
KEYNOTE-001 Findings Show Responses Are Durable and Include Two Year Overall Survival Data for KEYTRUDA

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced new data, including updated response rates,
progression-free survival (PFS) and overall survival (OS) with KEYTRUDA®
(pembrolizumab), the company’s anti-PD-1 therapy, as a monotherapy in
patients with advanced non-small cell lung cancer (NSCLC) whose tumors
express PD-L1 from two studies: KEYNOTE-010 and KEYNOTE-001.
Language:

English

Contact:

MerckMedia Contacts:Pamela Eisele, [phone]orCourtney Ronaldo, [phone]orInvestor Contacts:Teri Loxam, [phone]orJustin Holko, [phone]

Ticker Slug:

Ticker: MRK Exchange: NYSE

read more

Source: Merck.com - Research and Development News - June 4, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO cancer Keytruda MSD Source Type: news